1822505-24-7 Usage
Description
(±)-trans-ethyl 4-hydroxytetrahydro-2H-pyran-2-carboxylate is a chemical compound characterized by the molecular formula C9H14O5. It is a derivative of tetrahydro-2H-pyran-2-carboxylic acid, known for its potential biological activities and pharmacological effects. (±)-trans-ethyl 4-hydroxytetrahydro-2H-pyran-2-carboxylate serves as a valuable building block in the pharmaceutical industry for the synthesis of a variety of drugs.
Uses
Used in Pharmaceutical Industry:
(±)-trans-ethyl 4-hydroxytetrahydro-2H-pyran-2-carboxylate is utilized as a key intermediate in the synthesis of medicinally important substances. Its unique properties make it suitable for creating a range of pharmaceuticals that can address various health conditions.
Used in Drug Development:
As a compound with potential biological activities, (±)-trans-ethyl 4-hydroxytetrahydro-2H-pyran-2-carboxylate is studied for its possible pharmacological effects. This research aims to explore its therapeutic potential and incorporate it into the development of new drugs that can offer novel treatment options for patients.
Used in Chemical Research:
(±)-trans-ethyl 4-hydroxytetrahydro-2H-pyran-2-carboxylate's structure and properties also make it a subject of interest in chemical research. Scientists investigate its reactivity, stability, and interactions with other molecules to gain insights that can lead to advancements in the field of chemistry and related disciplines.
Check Digit Verification of cas no
The CAS Registry Mumber 1822505-24-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,2,2,5,0 and 5 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1822505-24:
(9*1)+(8*8)+(7*2)+(6*2)+(5*5)+(4*0)+(3*5)+(2*2)+(1*4)=147
147 % 10 = 7
So 1822505-24-7 is a valid CAS Registry Number.
1822505-24-7Relevant articles and documents
ISOXAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS
-
Page/Page column 105-106, (2021/01/22)
The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
